CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
Open Access
- 31 October 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 70 (5), 1239-1254
- https://doi.org/10.1007/s00262-020-02742-1
Abstract
Glioblastoma is the most common and aggressive type of brain tumor with high recurrence and fatality rates. Although various therapeutic strategies have been explored, there is currently no effective treatment for glioblastoma. Recently, the number of immunotherapeutic strategies has been tested for malignant brain tumors. Invariant natural killer T (iNKT) cells play an important role in anti-tumor immunity. To address if iNKT cells can target glioblastoma to exert anti-tumor activity, we assessed the expression of CD1d, an antigen-presenting molecule for iNKT cells, on glioblastoma cells. Glioblastoma cells from 10 of 15 patients expressed CD1d, and CD1d-positive glioblastoma cells pulsed with glycolipid ligand induced iNKT cell-mediated cytotoxicity in vitro. Although CD1d expression was low on glioblastoma stem-like cells, retinoic acid, which is the most common differentiating agent, upregulated CD1d expression in these cells and induced iNKT cell-mediated cytotoxicity. Moreover, intracranial administration of human iNKT cells induced tumor regression of CD1d-positive glioblastoma in orthotopic xenografts in NOD/Shi-scid IL-2RγKO (NOG) mice. Thus, CD1d expression represents a novel target for NKT cell-based immunotherapy for glioblastoma patients.Keywords
Funding Information
- Japan Society for the Promotion of Science (#18H0289, #17K16625, #19K18379)
This publication has 35 references indexed in Scilit:
- Immunotherapy for Glioblastoma: Playing Chess, Not CheckersClinical Cancer Research, 2018
- Current status and future directions of cancer immunotherapyJournal of Cancer, 2018
- Recurrent glioma clinical trial, CheckMate-143: the game is not over yetOncotarget, 2017
- Advances in immunotherapy for the treatment of glioblastomaJournal of Neuro-Oncology, 2016
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Neural Stem Cells and the Origin of GliomasThe New England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Identification of human brain tumour initiating cellsNature, 2004
- Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human GlioblastomaCancer Research, 2004
- Disguising adult neural stem cellsCurrent Opinion in Neurobiology, 2004